BioDlink International Announces Board and Committee Restructuring
I'm PortAI, I can summarize articles.
BioDlink International Company Limited has announced a restructuring of its board and committees effective October 11, 2025. Mr. Fu Shan will chair the Strategy and ESG Committee, with Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin taking roles in various committees. This restructuring aims to improve governance and strategic oversight. The current analyst rating for TOT BIOPHARM International Co. Ltd. (HK:1875) is a Hold with a price target of HK$2.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments